BFORCURE

Their core work

BFORCURE is a French SME specializing in microfluidics-based diagnostic devices, particularly rapid PCR platforms for infectious disease detection. They develop miniaturized lab-on-a-chip systems that bring laboratory-grade molecular diagnostics to point-of-care settings. Their core product line centers on integrating quantitative PCR (qPCR) into compact microfluidic chips, targeting diseases like dengue and urinary tract infections where fast, on-site diagnosis is critical.

What they specialise in

How they've shifted over time

BFORCURE's trajectory shows a clear progression from standalone PCR diagnostic concepts toward fully integrated microfluidic platforms. Their early projects (FIT-UTI in 2017, Smartpolymer in 2019) focused on improving PCR chemistry and sensitivity for specific clinical applications. By 2020-2023, with DENVPOC and NORAMID SE, the focus shifted decisively to complete point-of-care systems — combining microfluidics, microfabrication, and nucleic acid processing into single-device solutions for infectious disease diagnosis.

BFORCURE is moving toward fully integrated, field-deployable molecular diagnostic devices — expect future work on multi-pathogen detection chips and regulatory-ready POC systems.

How they like to work

BFORCURE operates exclusively as a project coordinator — all four H2020 grants were MSCA Individual Fellowships where they hosted researchers. This means they function as a host company attracting scientific talent rather than building large consortia. With only 1 unique consortium partner across all projects, they work in a highly self-contained mode, using EU funding primarily to bring in specialized researchers to advance their own product R&D.

BFORCURE has a minimal consortium network — just 1 unique partner in 1 country across all projects. Their H2020 participation is built entirely around MSCA fellowships hosted at their own facility, not collaborative multi-partner consortia.

What sets them apart

BFORCURE occupies a rare niche: a private SME that consistently attracts Marie Skłodowska-Curie fellows to work on commercial diagnostic technology. This signals a company with genuine R&D depth that academic researchers want to join, not just a typical SME subcontractor. For potential partners, they offer hands-on microfluidic device engineering with a clear path from lab prototype to diagnostic product — the kind of translational capability that academic groups often lack.

Highlights from their portfolio

• NORAMID SE
  Their most recent and ambitious project, integrating nucleic acid isolation directly into their FASTGENE PCR microfluidic device — represents the culmination of their full-system integration strategy.
• DENVPOC
  Targeted a specific global health challenge (dengue diagnosis) with a complete qPCR microfluidic point-of-care platform, showing readiness for real-world deployment scenarios.
• Smartpolymer
  Expanded their capability beyond hardware into smart polymer chemistry for multiplex assays, broadening the range of pathogens their platform can detect simultaneously.